Abstract: The invention relates to a process for producing a material based on silver-carbon, that involves the steps of: (i) providing a suspension of carbon particles; and (ii) supplying a solution of a silver compound and of a reducing agent, such that a silver-containing precipitate is deposited onto the carbon particles, where the carbon particles have a mean diameter of 200 nm or greater. The invention further relates to a material obtainable by this process and to the use of the material in circuit breakers for low-voltage power engineering.

Abstract: An ink is disclosed for producing membrane electrode assemblies for fuel cells which contains a catalyst material, an ionomer, water and an organic solvent. The ink is characterized in that the organic solvent is at least one compound from the group of linear dialcohols with a flash point higher than 100° C. and is present in the ink in a concentration between 1 and 50 wt. %, with respect to the weight of water.

Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for IRAK4.

Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CDK11.

Abstract: Nucleoside phosphinoamidite carboxylates and analogs are provided that have the structure of formula (III) wherein A is hydrogen, hydroxyl, lower alkoxy, lower alkoxy-substituted lower alkoxy, halogen, SH, NH2, azide or DL wherein D is O, S or NH and L is a heteroatom-protecting group, unsubstituted hydrocarbyl, substituted hydrocarbyl, heteroatom-containing hydrocarbyl, or substituted heteroatom-containing hydrocarbyl; B is a nucleobase; and one of R11 and R12 is a blocking group and the other is (IV) or (VI) in which W, X, Y, Z, R1 and n are as defined herein.

Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs directed to silencing KRAS, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.

Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CKSF1B1.

Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.

Abstract: This invention relates to a method of operating a catalyst for treating the exhaust gas of an internal combustion engine, the catalyst comprising, in addition to catalytically active noble metals, also storage components for storing hydrocarbons. During engine operating phases at low exhaust-gas temperatures, such a catalyst stores the hydrocarbons contained in the exhaust gas without burning them. When the exhaust-gas temperature rises, these hydrocarbons are desorbed again and then oxidized at the catalytically active noble metals. This process can lead to uncontrolled, vigorous combustion of the hydrocarbons stored on the catalyst and, therefore, damage to the catalyst. According to the invention, this damage is avoided by continuously calculating the respective loading of the storage components with hydrocarbons and repeatedly regenerating the storage components depending on the loading by temporarily raising the exhaust-gas temperature before damage to the catalyst can occur.

Abstract: When a nitrogen oxide storage catalyst is being regenerated, the regeneration may be terminated for example as a result of a premature load change in the engine, which can lead to incomplete emptying of the storage catalyst. The residual filling level which remains in the catalyst following an incomplete regeneration of this nature is used as the starting value for calculation of the filling level during the next storage phase. After incomplete regeneration, the nitrogen oxide conversion rate is initially greater than would be expected, on account of the residual filling level. By taking this increased conversion rate into account when calculating the filling level during the storage phase, it is possible to further improve the accuracy of the calculation.

Abstract: The present invention provides a method for manufacture of supported noble metal based alloy catalysts with a high degree of alloying and a small crystallite size. The method is based on the use of polyol solvents as reaction medium and comprises of a two-step reduction process in the presence of a support material. In the first step, the first metal (M1=transition metal; e.g. Co, Cr, Ru) is activated by increasing the reaction temperature to 80 to 160° C. In the second step, the second metal (M2=noble metal; e.g. Pt, Pd, Au and mixtures thereof) is added and the slurry is heated to the boiling point of the polyol solvent in a range of 160 to 300° C. Due to this two-step method, an uniform reduction occurs, resulting in noble metal based catalysts with a high degree of alloying and a small crystallite size of less than 3 nm. Due to the high degree of alloying, the lattice constants are lowered.

Abstract: The present invention includes a diagnostic assay for the detection and determination of MGP in a human serum sample, which comprises the use of one or more antibodies, preferably monoclonal antibodies, specifically recognizing epitopes on and/or conformations of human Matrix Gla-Protein. A method is provided for using MGP-related antigens as biomarkers for certain diseases, for example, atherosclerosis and other vascular diseases, and angiogenesis/neogenesis in tumor development. Monoclonal antibodies of class IgG are described for use in the assay, which are defined herein as mAb3-15, mAb35-49[Glu], mAb35-49[Gla], mAb35-53[Glu], and mAb35-53[Gla]. Polyclonal antibodies and methods are also disclosed for measuring MGP in a human serum sample.